Bone Marrow Transplant is a $1.3 billion per year market in the US based on 2007 data. In the US, over the period from 2004 – 2007 (most recent available data) it was the hospital procedure with fastest growing number of hospital stays (51.3% growth, 15,100 hospital stays in 2007) and aggregate cost growth (84.9% growth, $1.3 BN in 2007). The cost increase is mostly due to the increase in the number of procedures (the majority of the 84.9% cost growth) and to a smaller extent, the increase in mean cost of hospital stay (25.6% contributor to the 84.9% cost growth) (Healthcare Cost and Utilization Project, December 2009, US Government Agency for Healthcare Research and Quality).
In 2010, about 20,000 BMTs were performed in the US. Approximately 12,000 were autologous and approximately 8,000 were allogeneic. Worldwide, there were about 60,000 BMTs overall, about 34,000 autologous and 26,000 allogeneic (Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010, Center For International Blood & Bone Marrow Transplant Research). The number of patients over the age of 50 has been steadily increasing over the last decade and based on the latest available data grew from 8% in 2000 to 21% in 2005 and 27% in 2007 (Biology of Blood and Marrow Transplantation Volume 14, Issue 9, September 2008).